PCN57 Budget IMPACT Analysis of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Metastatic Disease in Greece.

G Gourzoulidis,N Androulakis,A Beletsi,G Kourlaba,V Chotzagiannoglou,S Xynogalos,P Papakotoulas,I Souglakos,E Samantas,M Karamouzis,A Koumarianou,I Boukovinas,M Koulentaki

doi:10.1016/j.jval.2020.08.194

PCN57 Budget IMPACT Analysis of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Metastatic Disease in Greece.

G Gourzoulidis, N Androulakis + Show 11 more

Open Access

https://doi.org/10.1016/j.jval.2020.08.194

Copy DOI

Journal: Value in Health	Publication Date: Dec 1, 2020
License type: publisher-specific-oa

Affiliation: The General Hospital of Heraklion "Venizeleio-Pananio", Space Hellas (Greece), Metaxa Hospital, Theageneio General Hospital, University Hospital of Heraklion, Metropolitan Hospital, National and Kapodistrian University of Athens

#PRIOR Therapies For Metastatic Disease #Treatment Of Metastatic Gastric Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PCN57 Budget IMPACT Analysis of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Metastatic Disease in Greece.

Full Text